Seitaro Yoshida

704 total citations
14 papers, 471 citations indexed

About

Seitaro Yoshida is a scholar working on Statistics and Probability, Economics and Econometrics and Oncology. According to data from OpenAlex, Seitaro Yoshida has authored 14 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Statistics and Probability, 4 papers in Economics and Econometrics and 3 papers in Oncology. Recurrent topics in Seitaro Yoshida's work include Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Bone health and treatments (3 papers). Seitaro Yoshida is often cited by papers focused on Statistical Methods in Clinical Trials (5 papers), Health Systems, Economic Evaluations, Quality of Life (4 papers) and Bone health and treatments (3 papers). Seitaro Yoshida collaborates with scholars based in Japan, United States and Australia. Seitaro Yoshida's co-authors include Yoshikazu Nakaoka, Shumpei Yokota, Yoshiya Tanaka, Akira Nomura, Norihiro Nishimoto, Syuji Takei, Mitsuaki Isobe, Tomonori Ishii, Akira Ishiguro and Keiji Nogami and has published in prestigious journals such as Blood, Annals of the Rheumatic Diseases and Journal of Hypertension.

In The Last Decade

Seitaro Yoshida

14 papers receiving 464 citations

Peers

Seitaro Yoshida

PRM

HEMAT

RHEUM

NEPHR

IMMUN

E. N. Griep Netherlands

Hirofumi Tamai Japan

Achra Sumboonnanonda Thailand

Samar Marzouk Egypt

Mirit Amit-Vazina Israel

Peter Poon Hong Kong

Hee Yeon Cho South Korea

Sean Barbour Canada

Michelle Sonneveld Netherlands

J F M Wetzels Netherlands

E. N. Griep Netherlands

Seitaro Yoshida

22 ×0.1

PRM

73 ×0.5

HEMAT

350 ×3.0

RHEUM

121 ×1.6

NEPHR

84 ×1.1

IMMUN

Citations per year, relative to Seitaro Yoshida Seitaro Yoshida (= 1×) peers E. N. Griep

Countries citing papers authored by Seitaro Yoshida

Since Specialization

Citations

This map shows the geographic impact of Seitaro Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seitaro Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seitaro Yoshida more than expected).

Fields of papers citing papers by Seitaro Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seitaro Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seitaro Yoshida. The network helps show where Seitaro Yoshida may publish in the future.

Co-authorship network of co-authors of Seitaro Yoshida

This figure shows the co-authorship network connecting the top 25 collaborators of Seitaro Yoshida. A scholar is included among the top collaborators of Seitaro Yoshida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seitaro Yoshida. Seitaro Yoshida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Shima, Midori, Hideyuki Takedani, Masashi Taki, et al.. (2022). AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab – protocol for a multicentre, open-label, phase IV clinical study. BMJ Open. 12(6). e059667–e059667. 4 indexed citations

Sakamaki, Kentaro, et al.. (2020). Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. Therapeutic Innovation & Regulatory Science. 54(3). 528–533. 1 indexed citations

Sakamaki, Kentaro, et al.. (2020). Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan. Therapeutic Innovation & Regulatory Science. 54(5). 1097–1105. 2 indexed citations

Sakamaki, Kentaro, et al.. (2019). Challenges on Multiple Endpoints in Clinical Trials: An Industry Survey in Japan. Therapeutic Innovation & Regulatory Science. 54(3). 3593145151–3593145151. 2 indexed citations

Shima, Midori, Keiji Nogami, Seitaro Yoshida, et al.. (2019). A multicentre, open‐label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia. 25(6). 979–987. 113 indexed citations

Shima, Midori, Keiji Nogami, Seitaro Yoshida, et al.. (2018). Every 2 Weeks or Every 4 Weeks Subcutaneous Injection of Emicizumab in Pediatric Patients with Severe Hemophilia A without Inhibitors: A Multi-Center, Open-Label Study in Japan (HOHOEMI Study). Blood. 132(Supplement 1). 1186–1186. 8 indexed citations

Nakaoka, Yoshikazu, Mitsuaki Isobe, Syuji Takei, et al.. (2017). Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Annals of the Rheumatic Diseases. 77(3). 348–354. 222 indexed citations

Sakamaki, Kentaro, et al.. (2016). Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials: An Industry Survey in Japan. Therapeutic Innovation & Regulatory Science. 50(6). 846–852. 2 indexed citations

Hirayasu, Yoshio, Shinichi Sato, Hideaki Takahashi, et al.. (2016). A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. BMC Psychiatry. 16(1). 66–66. 28 indexed citations

10.

Yoshida, Seitaro & Kentaro Sakamaki. (2015). Gatekeeping Procedure in Confirmatory Clinical Trials. 36(Special_Issue_2). S165–S171. 1 indexed citations

11.

Nakano, Tetsuo, et al.. (2015). Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. Journal of Bone and Mineral Metabolism. 34(6). 678–684. 8 indexed citations

12.

Ito, Masako, et al.. (2015). Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. Journal of Bone and Mineral Metabolism. 35(1). 58–64. 12 indexed citations

13.

Hagino, Hiroshi, et al.. (2014). Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study. Calcified Tissue International. 95(6). 557–563. 18 indexed citations

14.

Asayama, Kei, Takayoshi Ohkubo, Seitaro Yoshida, et al.. (2009). Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. Journal of Hypertension. 27(2). 357–364. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact